Coherus Oncology, Inc. (CHRS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 150M 300M 450M Q3 '21: 363.6M Q4 '21: 326.6M Q1 '22: 303.6M Q2 '22: 276.1M Q3 '22: 239.1M Q4 '22: 211M Q1 '23: 183.4M Q2 '23: 181.9M Q3 '23: 211.1M Q4 '23: 257.2M Q1 '24: 227.1M Q2 '24: 178.7M Q3 '24: 110.2M Q4 '24: 26.4M Q1 '25: 31.7M Q2 '25: 31.6M Q3 '25: 37.2M Q4 '25: 42.2M Q1 '26: 46.9M Q2 '26: 50.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

0 150M 300M 450M Q4 '19: 339M Q4 '19

Operating Income TTM

-270M -180M -90M 0 90M 180M 270M Q3 '21: -207.9M Q4 '21: -263.9M Q1 '22: -177.4M Q2 '22: -197.3M Q3 '22: -244.9M Q4 '22: -256.9M Q1 '23: -243.7M Q2 '23: -234.2M Q3 '23: -185.8M Q4 '23: -203.2M Q1 '24: -203.2M Q2 '24: -208.3M Q3 '24: -223.2M Q4 '24: -199.7M Q1 '25: -177.3M Q2 '25: -183.2M Q3 '25: -180.6M Q4 '25: -181.1M Q1 '26: -171.8M Q2 '26: -158.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-300M -200M -100M 0 100M 200M 300M Q3 '21: -231.7M Q4 '21: -287.1M Q1 '22: -210.2M Q2 '22: -230.5M Q3 '22: -278.6M Q4 '22: -291.8M Q1 '23: -271.4M Q2 '23: -264.1M Q3 '23: -217.1M Q4 '23: -237.9M Q1 '24: -59.3M Q2 '24: -29.3M Q3 '24: -450K Q4 '24: 28.5M Q1 '25: -130.9M Q2 '25: 179.8M Q3 '25: 155M Q4 '25: 168M Q1 '26: 186.3M Q2 '26: -132.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 60M 120M 180M Q3 '21: 57.2M Q4 '21: 57.6M Q1 '22: 59.5M Q2 '22: 54M Q3 '22: 68M Q4 '22: 70.1M Q1 '23: 77.6M Q2 '23: 91.2M Q3 '23: 88.6M Q4 '23: 159M Q1 '24: 143.6M Q2 '24: 120.5M Q3 '24: 90.5M Q4 '24: 8.7M Q1 '25: 9.9M Q2 '25: 11.5M Q3 '25: 12.5M Q4 '25: 13.8M Q1 '26: 15M Q2 '26: 15.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

-270M -180M -90M 0 90M 180M 270M Q3 '21: 48M Q4 '21: -37.4M Q1 '22: -92.8M Q2 '22: -142.7M Q3 '22: -193.5M Q4 '22: -241.1M Q1 '23: -255.8M Q2 '23: -244.7M Q3 '23: -261.9M Q4 '23: -174.9M Q1 '24: -152.9M Q2 '24: -54.3M Q3 '24: -62M Q4 '24: -20.4M Q1 '25: 500K Q2 '25: -105.9M Q3 '25: -90.2M Q4 '25: -138.5M Q1 '26: -170.6M Q2 '26: -186M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-270M -180M -90M 0 90M 180M 270M Q1 '19: -183.7M Q2 '19: -135.7M Q3 '19: -38.4M Q4 '19: 26.5M Q1 '20: 95.5M Q2 '20: 140.9M Q3 '20: 132.1M Q4 '20: 146.9M Q1 '21: 136.4M Q2 '21: 78M Q3 '21: 46.2M Q4 '21: -38.7M Q1 '22: -94.6M Q2 '22: -144.9M Q3 '22: -195.9M Q4 '22: -243.2M Q1 '23: -257.4M Q2 '23: -245.5M Q3 '23: -262.2M Q4 '23: -175.2M Q2 '19 Q1 '20 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 60M 120M 180M Q1 '20: 74.4M Q2 '20: 88.7M Q3 '20: 87.5M Q1 '21: 72.8M Q2 '21: 75.6M Q3 '21: 79M Q1 '22: 77.3M Q2 '22: 77.6M Q3 '22: 77.7M Q1 '23: 79.3M Q2 '23: 87.3M Q3 '23: 97.7M Q1 '24: 112.7M Q2 '24: 114.8M Q3 '24: 115.2M Q1 '25: 116.1M Q2 '25: 116.1M Q3 '25: 116.2M Q1 '26: 136.4M Q2 '26: 154.8M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q2 '20: 2.34 Q3 '20: 2.04 Q4 '20: 1.61 Q1 '21: -1.24 Q2 '21: -2.34 Q3 '21: -3.16 Q4 '21: -3.85 Q1 '22: -2.72 Q2 '22: -2.97 Q3 '22: -3.59 Q4 '22: -3.76 Q1 '23: -3.48 Q2 '23: -3.32 Q3 '23: -2.62 Q4 '23: -2.60 Q1 '24: -0.73 Q2 '24: -0.35 Q3 '24: -0.03 Q1 '26: -1.42 Q2 '26: -4.12 Q3 '20 Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.